Advances in Immunotherapy for Transplant Oncology

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Jul 13

PMID 39001431

Authors

Maen Abdelrahim

Abdullah Esmail

Aiwu Ruth He

Mohd Khushman

Yaser Rayyan

Affiliations

Soon will be listed here.

Abstract

The increasing incidence of global cancer rates has created an entirely new demand for curative treatment modalities to improve patient outcomes [...].

Citing Articles

Focal Update on Immunotherapy and Liver Transplantation in the Era of Transplant Oncology.

Abdelrahim M, Esmail A, Hibi T, Mazzaferro V Curr Oncol. 2024; 31(9):5021-5026.

PMID: 39329999 PMC: 11430635. DOI: 10.3390/curroncol31090371.

The Recent Trends of Systemic Treatments and Locoregional Therapies for Cholangiocarcinoma.

Esmail A, Badheeb M, Alnahar B, Almiqlash B, Sakr Y, Al-Najjar E Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065760 PMC: 11279608. DOI: 10.3390/ph17070910.

References

Skipworth J, Keane M, Pereira S . Update on the management of cholangiocarcinoma. Dig Dis. 2014; 32(5):570-8. PMC: 4158615. DOI: 10.1159/000360507. View

Xu X, Lu D, Ling Q, Wei X, Wu J, Zhou L . Liver transplantation for hepatocellular carcinoma beyond the Milan criteria. Gut. 2015; 65(6):1035-41. PMC: 4893115. DOI: 10.1136/gutjnl-2014-308513. View

Reichman T, Katchman H, Tanaka T, Greig P, McGilvray I, Cattral M . Living donor versus deceased donor liver transplantation: a surgeon-matched comparison of recipient morbidity and outcomes. Transpl Int. 2013; 26(8):780-7. DOI: 10.1111/tri.12127. View

Alghamdi S, Al-Hamoudi W . Hepatocellular Carcinoma: The Role of Immunotherapy and Transplantation in the Era of Transplant Oncology. Cancers (Basel). 2023; 15(21). PMC: 10648843. DOI: 10.3390/cancers15215115. View

Fisher R, Cotterell A, Maluf D, Stravitz R, Ashworth A, Nakatsuka M . Adult living donor versus deceased donor liver transplantation: a 10-year prospective single center experience. Ann Hepatol. 2009; 8(4):298-307. View

Mehta N, Heimbach J, Harnois D, Sapisochin G, Dodge J, Lee D . Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant. JAMA Oncol. 2016; 3(4):493-500. PMC: 5395317. DOI: 10.1001/jamaoncol.2016.5116. View

Rizzo A, Brandi G . Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review. Cancer Treat Res Commun. 2021; 27:100354. DOI: 10.1016/j.ctarc.2021.100354. View

Wassmer C, El Hajji S, Papazarkadas X, Compagnon P, Tabrizian P, Lacotte S . Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data. Cancers (Basel). 2023; 15(18). PMC: 10526934. DOI: 10.3390/cancers15184574. View

Yao F, Xiao L, Bass N, Kerlan R, Ascher N, Roberts J . Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant. 2007; 7(11):2587-96. DOI: 10.1111/j.1600-6143.2007.01965.x. View

10.

Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F . Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334(11):693-9. DOI: 10.1056/NEJM199603143341104. View

11.

Abdelrahim M, Esmail A, Divatia M, Xu J, Kodali S, Victor D . Utilization of Immunotherapy as a Neoadjuvant Therapy for Liver Transplant Recipients with Hepatocellular Carcinoma. J Clin Med. 2024; 13(11). PMC: 11172993. DOI: 10.3390/jcm13113068. View

12.

Safarpour A, Askari H, Ejtehadi F, Azarnezhad A, Raeis-Abdollahi E, Tajbakhsh A . Cholangiocarcinoma and liver transplantation: What we know so far?. World J Gastrointest Pathophysiol. 2021; 12(5):84-105. PMC: 8481789. DOI: 10.4291/wjgp.v12.i5.84. View

13.

Zhang Y, Esmail A, Mazzaferro V, Abdelrahim M . Newest Therapies for Cholangiocarcinoma: An Updated Overview of Approved Treatments with Transplant Oncology Vision. Cancers (Basel). 2022; 14(20). PMC: 9600404. DOI: 10.3390/cancers14205074. View

14.

Ghio M, Vijay A . Intrahepatic cholangiocarcinoma: Evolving role of neoadjuvant and targeted therapy. Ann Hepatobiliary Pancreat Surg. 2023; 27(2):123-130. PMC: 10201062. DOI: 10.14701/ahbps.22-110. View

15.

Abdelrahim M, Esmail A, Abudayyeh A, Murakami N, Victor D, Kodali S . Transplant Oncology: An Emerging Discipline of Cancer Treatment. Cancers (Basel). 2023; 15(22). PMC: 10670243. DOI: 10.3390/cancers15225337. View

16.

Soejima Y, Taketomi A, Yoshizumi T, Uchiyama H, Aishima S, Terashi T . Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. Transplantation. 2007; 83(7):893-9. DOI: 10.1097/01.tp.0000259015.46798.ec. View

17.

Llovet J, Kelley R, Villanueva A, Singal A, Pikarsky E, Roayaie S . Hepatocellular carcinoma. Nat Rev Dis Primers. 2021; 7(1):6. DOI: 10.1038/s41572-020-00240-3. View

18.

Esmail A, Badheeb M, Alnahar B, Almiqlash B, Sakr Y, Khasawneh B . Cholangiocarcinoma: The Current Status of Surgical Options including Liver Transplantation. Cancers (Basel). 2024; 16(11). PMC: 11171350. DOI: 10.3390/cancers16111946. View

19.

Abboud K, Umoru G, Esmail A, Abudayyeh A, Murakami N, Al-Shamsi H . Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology. Cancers (Basel). 2023; 15(5). PMC: 10000896. DOI: 10.3390/cancers15051433. View

20.

Chamseddine S, LaPelusa M, Kaseb A . Systemic Neoadjuvant and Adjuvant Therapies in the Management of Hepatocellular Carcinoma-A Narrative Review. Cancers (Basel). 2023; 15(13). PMC: 10340217. DOI: 10.3390/cancers15133508. View